Beacon Hospital in Dublin, Ireland has deployed the SRT-100 System, a superficial radiotherapy machine from Sensus Healthcare.
The system is designed to provide a non-invasive solution to treat non-melanoma skin cancer patients.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
This device allows doctors to provide non-surgical superficial radiotherapy treatments for patients with non-melanoma skin cancers, such as squamous cell carcinoma and basal cell carcinoma. It can also be used in the management of keloid scars.
As per estimates by the Irish Cancer Society, non-melanoma skin cancer impacts over 12,000 people in the country per year.
Beacon Hospital lead radiation oncologist Siobhra O’Sullivan said: “We are delighted to announce expansion of our radiotherapy services at Beacon Hospital, Dublin, with the delivery of the Sensus SRT-100.
“At Beacon Hospital, our skin cancer services are provided by a multidisciplinary team of radiation oncologists, plastic surgeons, dermatologists, and medical oncologists, to provide patients we serve with the most advanced and proven treatments.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe hospital features 181 inpatients beds, 70 day-case beds, eight operating theatres, two cath labs, four endoscopy suites, among others.
Sensus Healthcare chairman and CEO Joe Sardano said: “Beacon will serve as an example to the Irish dermato-oncology community of innovation in patient care. We expect that this system will be the first of many placed not only in Ireland, but in the United Kingdom as well.”
Sensus Healthcare provides low-energy X-ray technology, called superficial radiation therapy (SRT), for the treatment of non-melanoma skin cancers as well as keloids.
Its offerings include the SRT-100, SRT-100+ and SRT-100 Vision systems.
